Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
INFECTIOUS DISEASES / CLINICAL RESEARCH
COVID-19 disease: novel clinical manifestations and therapeutic exploration
1
Department of Critical Care Medicine, Dazhou Central Hospital, Sichuan Province, China
2
Department of Critical Care Medicine, Wenjiang District People’s Hospital, Chengdu-Sichuan Province, China
3
Science and Education-Dazhou Central Hospital, Sichuan Province, China
4
Department of Respiratory Medicine, Affiliated Hospital of Southwest Medical University, Sichuan Province, China
5
Imaging Center, Dazhou Central Hospital, Sichuan Province, China
Submission date: 2020-05-19
Final revision date: 2020-07-16
Acceptance date: 2020-08-03
Online publication date: 2020-08-25
Publication date: 2026-08-28
Corresponding author
Arch Med Sci 2026;22(4):2168-2174
KEYWORDS
TOPICS
ABSTRACT
Introduction:
This study aims to provide further clarifications on some new clinical characteristics of COVID-19 recently discovered by our research group.
Material and methods:
In this single-centred, retrospective study, we collected all confirmed cases of COVID-19 diagnosed in Dazhou, Sichuan, China from January 23 to February 25, 2020. All the cases were either imported from Wuhan or transmitted in family clusters. We analysed general information on all patients. Meanwhile, the contents of lactic acid, fibrinogen C (Fib-C), and D-dimer in the serum of patients were detected.
Results:
The study included 37 patients diagnosed as having COVID-19, the average age of the patients was 45.76 ±13.1 years. The average positive time of nucleic acid in pharyngeal swabs was 20.65 ±6.7 days. A total of 4 (10.8%) patients were asymptomatic. On serological examination, 33 (89.1%) patients had increased lactic acid, 17 patients had increased Fib-C, and 5 patients had increased D-dimer. Of all patients, 29 were positive for COVID-19-specific antibodies. We also detected COVID-19 nucleic acid in faecal specimens from 4 patients. Klebsiella pneumoniae was found in the sputum of 1 patient. A total of 4 patients received psychological intervention. Lopinavir/ritonavir and Abidol may not be effective in treating COVID-19.
Conclusions:
In the serum of most COVID-19-infected patients, lactic acid was higher than normal, and COVID-19-specific antibody was positive. Fib-C and D-dimer in the serum of some infected patients increased. Lopinavir/ritonavir and Abidol have little effect on shortening the positive time of viral nucleic acid in patients.
This study aims to provide further clarifications on some new clinical characteristics of COVID-19 recently discovered by our research group.
Material and methods:
In this single-centred, retrospective study, we collected all confirmed cases of COVID-19 diagnosed in Dazhou, Sichuan, China from January 23 to February 25, 2020. All the cases were either imported from Wuhan or transmitted in family clusters. We analysed general information on all patients. Meanwhile, the contents of lactic acid, fibrinogen C (Fib-C), and D-dimer in the serum of patients were detected.
Results:
The study included 37 patients diagnosed as having COVID-19, the average age of the patients was 45.76 ±13.1 years. The average positive time of nucleic acid in pharyngeal swabs was 20.65 ±6.7 days. A total of 4 (10.8%) patients were asymptomatic. On serological examination, 33 (89.1%) patients had increased lactic acid, 17 patients had increased Fib-C, and 5 patients had increased D-dimer. Of all patients, 29 were positive for COVID-19-specific antibodies. We also detected COVID-19 nucleic acid in faecal specimens from 4 patients. Klebsiella pneumoniae was found in the sputum of 1 patient. A total of 4 patients received psychological intervention. Lopinavir/ritonavir and Abidol may not be effective in treating COVID-19.
Conclusions:
In the serum of most COVID-19-infected patients, lactic acid was higher than normal, and COVID-19-specific antibody was positive. Fib-C and D-dimer in the serum of some infected patients increased. Lopinavir/ritonavir and Abidol have little effect on shortening the positive time of viral nucleic acid in patients.
REFERENCES (34)
1.
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-20.
2.
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-13.
3.
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382: 1787-99.
4.
Zhu S, Guo X, Geary K, et al. Emerging therapeutic strategies for COVID-19 patients. Discoveries 2020; 8: e105.
5.
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727-33.
6.
Liu Z, Xiao X, Wei X, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol 2020; 92: 595-601.
7.
Xu J, Zhao S, Teng T, et al. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses 2020; 12: 244.
8.
Wang LF, Shi Z, Zhang S, Field H, Daszak P, Eaton BT. Review of bats and SARS. Emerg Infect Dis 2006; 12: 1834-40.
9.
Ge XY, Li JL, Yang XL, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013; 503: 535-8.
10.
Chen Y, Guo D. Molecular mechanisms of coronavirus RNA capping and methylation. Virol Sin 2016; 31: 3-11.
11.
Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 2018; 23: 130-7.
12.
Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 2019; 11: 59.
13.
Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: an overview. J Chin Med Assoc 2020; 83: 217-20.
14.
New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 6). Tianjin Journal of Traditional Chinese Medicine: 1-5.
15.
Bai Y, Shi M, Yang X, et al. The value of FDP/FIB and D-dimer/FIB ratios in predicting high-risk APL-related thrombosis. Leuk Res 2019; 79: 34-7.
16.
Shi F, Yu A, Yuan L. Clinical significance of detection of coagulation indexes, immune factors and inflammatory factors in patients with pregnancy-induced hypertension syndrome in China. Iran J Public Health 2019; 48: 681-7.
17.
Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020; 58: 1116-20.
18.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62.
19.
Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020; 92: 791-6.
20.
Peng YD, Meng K, Guan HQ, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48: E004.
21.
Li Q, Liu PB, Qiao ZR, et al. The value of SARS-CoV-2 IgM/IgG antibody detection in the diagnosis of new coronavirus pneumonia. Int J Labor Med 1-10.
22.
Zhang J, Wang S, Xue Y. Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia. J Med Virol 2020; 92: 680-2.
23.
Xie C, Jiang L, Huang G, et al. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. Int J Infect Dis 2020; 93: 264-7.
24.
Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020; 9: 386-9.
25.
Sarda C, Palma P, Rello J. Severe influenza: overview in critically ill patients. Curr Opin Crit Care 2019; 25: 449-57.
26.
LeMessurier KS, Iverson AR, Chang TC, et al. Allergic inflammation alters the lung microbiome and hinders synergistic co-infection with H1N1 influenza virus and Streptococcus pneumoniae in C57BL/6 mice. Sci Rep 2019; 9: 19360.
27.
Gu L, Deng H, Ren Z, et al. Dynamic changes in the microbiome and mucosal immune microenvironment of the lower respiratory tract by influenza virus infection. Front Microbiol 2019; 10: 2491.
28.
Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin 2020; 35: 266-71.
29.
Cismaru A, Cismaru L, Nabavi SF, et al. Game of “crowning” season 8: RAS and reproductive hormones in COVID-19 – can we end this viral series? Arch Med Sci 2020; 17: 275-84.
30.
Katsiki N, Banach M, Mikhailidis DP. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. Arch Med Sci 2020; 16: 485-9.
31.
Reiner Ž, Hatamipour M, Banach M, et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci 2020; 16: 490-6.
32.
Bianconi V, Bronzo P, Banach M, et al. Particulate matter pollution and the COVID-19 outbreak: results from Italian regions and provinces. Arch Med Sci 2020; 16: 985-92.
33.
Azeez SA, Alhashim ZG, Al Otaibi WM, et al. State-of-the-art tools to identify druggable protein ligand of SARS-CoV-2. Arch Med Sci 2020; 16: 497-507.
34.
Borgio JF, Alsuwat HS, Al Otaibi WM, et al. State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2. Arch Med Sci 2020; 16: 508-18.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
